Hyperuricemia on Admission Predicts Short-Term Mortality due to Myocardial Infarction in a Population with High Prevalence of Cardiovascular Risk Factors

Mauricio Mora-Ramírez; Irving O Estevez-Garcia; María E Irigoyen-Camacho; Rafael Bojalil; Héctor Gonzalez-Pacheco; Luis M Amezcua-Guerra

2017, Número 5

<< Anterior Siguiente >>

Rev Invest Clin 2017; 69 (5)

Hyperuricemia on Admission Predicts Short-Term Mortality due to Myocardial Infarction in a Population with High Prevalence of Cardiovascular Risk Factors

Mora-Ramírez M, Estevez-Garcia IO, Irigoyen-Camacho ME, Bojalil R, Gonzalez-Pacheco H, Amezcua-Guerra LM

Texto completo

Cómo citar este artículo

Idioma: Ingles.
Referencias bibliográficas: 27
Paginas: 247-253
Archivo PDF: 100.37 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Manag Care. 2009; 15(Suppl):S36-41.
Gutiérrez J, Rivera-Dommarco J, Shamah-Levy T, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Salud Publica Mex. 2012;196.
Barquera S, Campos-Nonato I, Hernández-Barrera L, Pedroza A, Rivera-Dommarco JA. [Prevalence of obesity in Mexican adults 2000-2012]. Salud Publica Mex. 2013;55(Suppl 2): S151-60.
Campos-Nonato I, Hernández-Barrera L, Rojas-Martínez R, Pedroza A, Medina-García C, Barquera-Cervera S. [Hypertension: prevalence, early diagnosis, control and trends in Mexican adults]. Salud Publica Mex. 2013;55(Suppl 2):S144-50.
Jiménez-Corona A, Aguilar-Salinas CA, Rojas-Martínez R, Hernández- Ávila M. [Type 2 diabetes and frequency of prevention and control measures]. Salud Publica Mex. 2013;55(Suppl 2): S137-43.
López-Molina R, Parra-Cabrera S, López-Ridaura R, González- Villalpando ME, Ferrannini E, González-Villalpando C. Sweetened beverages intake, hyperuricemia and metabolic syndrome: the Mexico City Diabetes Study. Salud Publica Mex. 2013;55: 557-63.
WHO. Global Health Risks: Mortality and burden of disease attributable to selected major risks. Bull World Health Organ. 2009;87:646.
Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: Molecular mechanisms and clinical implications. J Cardiol. 2012;59:235-42.
Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7-13.
Lazzeri C, Valente S, Chiostri M, Sori A, Bernardo P, Gensini GF. Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. Int J Cardiol. 2010;138:206-9.
Ndrepepa G, Braun S, Haase H-U, et al. Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol. 2012;109:1260-5.
Kaya MG, Uyarel H, Akpek M, et al. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;109: 486-91.
Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. J Am Coll Cardiol. 2001;38:2114-30.
Williams DO, Abbott JD, Kip KE; DEScover Investigators. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: Report of the DEScover Registry. Circulation. 2006;114:2154-62.
Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63: 3136-41.
Stocker R, Keaney JF. New insights on oxidative stress in the artery wall. J Thromb Haemost. 2005;3:1825-34.
Alcaino H, Greig D, Chiong M, et al. Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail. 2008;10:646-51.
George J, Struthers AD. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag. 2009;5:265-72.
Godber BL, Doel JJ, Sapkota GP, et al. Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase. J Biol Chem. 2000;275:7757-63.
Meneshian A, Bulkley GB. The physiology of endothelial xanthine oxidase: From urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation. 2002;9:161-75.
Krishnan E, Pandya BJ, Chung L, Dabbous O. Hyperuricemia and the risk for subclinical coronary atherosclerosis - data from a prospective observational cohort study. Arthritis Res Ther. 2011; 13:R66.
Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep. 2011;13:160-6.
Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail. 2009;11:444-52.
Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med. 1999;160:487-92.
Lazzeri C, Valente S, Chiostri M, Picariello C, Gensini GF. Uric acid in the early risk stratification of ST-elevation myocardial infarction. Intern Emerg Med. 2012;7:33-9.
Kojima S, Sakamoto T, Ishihara M, et al. Prognostic usefulness of serum uric acid after acute myocardial infarction (The Japanese Acute Coronary Syndrome Study). Am J Cardiol. 2005;96:489-95.